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List of Clinical Trials
A to Z  Aggrastat to Zocor
ACUTE  Antithrombotic Combination Using Tirofi-
ban and Enoxaparin
ADMIRAL  Abciximab before Direct angioplasty and
stenting in Myocardial Infarction Regarding Acute and
Long-term follow-up
AFCAPS/TexCAPS  Air Force/Texas Coronary Ath-
erosclerosis Prevention Study
AMI-SK  Acute Myocardial Infarction-StreptoKinase
ASPECT Anticoagulants in the Secondary Prevention
of Events in Coronary Thrombosis
ASSENT  ASsessment of the Safety and Efficacy of a
New Thrombolytic
ATACS  Antithrombotic Therapy in Acute Coronary
Syndrome
BAAS  Balloon Angioplasty and Anticoagulation Study
BIOMACS  BIOchemical Markers in Acute Coronary
Syndromes
CADILLAC  Controlled Abciximab and Device In-
vestigation to Lower Late Angioplasty Complications
CAPARES  Coronary AngioPlasty Amlodipine RE-
stenosis Study
CAPRIE  Clopidogrel versus Aspirin in Patients at
Risk of Ischemic Events
CAPTURE  Chimeric c7E3 AntiPlatelet Therapy in
Unstable angina REfractory to standard treatment
CARE  Cholesterol And Recurrent Events
CARS  Coumadin Aspirin Reinfarction Study
CHAMP  Combination Hemotherapy And Mortality
Prevention
CHECKMATE  CHest pain Evaluation by Creatine
Kinase-MB, Myoglobin, And Troponin
CURE  Clopidogrel in Unstable angina to prevent
Recurrent ischemic Events
ENTIRE  ENoxaparin plus TNK-tPA with/without
GP IIb/IIIa as reperfusion for STEMI
EPIC  Evaluation of IIb/IIIa Platelet receptor antag-
onist 7E3 in Preventing Ischemic Complications
EPILOG Evaluation of PTCA to Improve Long-term
Outcome by c7E3 Glycoprotein IIb/IIIa receptor blockade
EPISTENT  Evaluation of Platelet IIb/IIIa Inhibition
for STENTing
ESSENCE  Efficacy and Safety of Subcutaneous
Enoxaparin in Non–Q-wave Coronary Events
FATS  Familial Atherosclerosis Treatment Study
FRAMI  FRAgmin in acute Myocardial Infarction
FRAXIS  FRAXiparine in Ischemic Syndromes
FRIC  FRagmin In unstable Coronary artery disease
FRISC FRagmin during InStability in Coronary artery
disease
GRAPE  Glycoprotein Receptor Antagonist Patency
Evaluation
GUSTO  Global Use of Strategies To Open occluded
arteries in acute coronary syndromes
HART  Heparins and Aspirin Reperfusion Therapy
HATS  High-density lipoprotein-Atherosclerosis
Treatment Study
HELVETICA  Hirudin in a European restenosis
prevention triaL VErsus heparin Treatment In PTCA
patients
HERO  Hirulog and Early Reperfusion or Occlusion
HIT  Hirudin for Improvement of Thrombolysis
HOPE  Heart Outcomes Prevention Evaluation
MIRACL  Myocardial Ischemia Reduction with Ag-
gressive Cholesterol Lowering
MONICA  MONItoring trends and determinants in
CArdiovascular disease
NICE  National Investigators Collaborating on Enox-
aparin
NORMALISE  NOrvasc for Regression of Manifest
Atherosclerotic Lesions by Intravascular Sonographic Eval-
uation
OASIS Organization to Assess Strategies for Ischemic
Syndromes
OPUS  Orbofiban in Patients with Unstable coronary
Syndromes
PACT  Pravastatin Acute Coronary Treatment
PARAGON  Platelet IIb/IIIa Antagonism for the
Reduction of Acute coronary syndrome events in a Global
Organization Network
PENTALYSE  PENTasaccharide as an Adjunct to
fibrinolysis in ST-Elevation Acute Myocardial Infarction
PENTUA  PENTasaccharide in Unstable Angina
POLONIA  POlish-American local LOvenox NIr
Assessment
PRISM-PLUS  Platelet Receptor inhibition for Isch-
emic Syndrome Management in Patients Limited to very
Unstable Signs and Symptoms
PROVE-IT  PRavastatin Or atorVastatin Evaluation
and Infection Therapy
PREVENT  Prospective Randomized Evaluation of
the Vascular Effects of Norvasc Trial
PURSUIT  Platelet glycoprotein IIb/IIIa in Unstable
angina: Receptor Suppression Using Integrilin Therapy
RAPPORT  ReoPro And Primary PTCA Organiza-
tion and Randomized Trial
RECIFE  REduction of Cholesterol in Ischemia and
Function of the Endothelium
REPLACE  Randomized Evaluation in PCI Linking
Angiomax to reduced Clinical Events
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REVERSAL  REVERSal of Atherosclerosis with
aggressive Lipid lowering
RISC  Research on InStability in Coronary artery
disease
RITA  Randomized Intervention Trial of unstable
Angina
SECURE  Study to Evaluate Carotid Ultrasound
changes in patients treated with Ramipril and Vitamin E
SPEED  Strategies for Patency Enhancement in the
Emergency Department
Stent-PAMI Stent Primary Angioplasty in Myocardial
Infarction
STOP-AMI  Stent versus Thrombolysis for Occluded
coronary arteries in Patients with Acute Myocardial Infarc-
tion
SYNERGY  Superior Yield of the New strategy of
Enoxaparin, Revascularization, and GlYcoprotein IIb/IIIa
inhibitors
TACTICS  Treat Angina with Aggrastat and deter-
mine Cost of Therapy with Invasive or Conservative Strat-
egy
TARGET  Do Tirofiban And Reopro Give Similar
Efficacy Trial
TETAMI Tirofiban and Enoxaparin in the Treatment
of Acute Myocardial Infarction
TIMI  Thrombolysis In Myocardial Infarction
TREND  Trial on Reversing ENdothelial Dysfunction
VANQWISH  Veterans Affairs Non–Q-Wave In-
hospital Strategies
WARIS  Warfarin-Aspirin ReInfarction Study
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